% Bibliography for hypothesis h-292a1ec3
% Title: Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade
% Generated: 2026-06-08T17:58:43Z

@article{pmid41824279,
  title = {First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.},
  author = {["Razak A", "Mahipal A", "Diamond JR", "Ribas A", "Berlin JD", "Azmi AS", "Mark T", "Walker CJ", "Chai Y", "Kashyap T", "Gudi G", "Naing A"]},
  journal = {Target Oncol},
  year = {2026},
  pmid = {41824279},
  doi = {10.1007/s11523-026-01206-3},
  url = {https://pubmed.ncbi.nlm.nih.gov/41824279/},
}

@article{pmid25709099,
  title = {Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.},
  author = {["Sampath D", "Zabka TS", "Misner DL", "O'Brien T", "Dragovich PS"]},
  journal = {Pharmacol Ther},
  year = {2015},
  pmid = {25709099},
  doi = {10.1016/j.pharmthera.2015.02.004},
  url = {https://pubmed.ncbi.nlm.nih.gov/25709099/},
}